|Dr. William W. Jow||CEO, Pres & Director||174k||N/A||1958|
|Mr. Mirsad Jakubovic C.A., M.B.A.||Chief Financial Officer||N/A||N/A||1962|
|Mr. John Mon||VP of Regulatory Affairs & Product Devel.||N/A||N/A||1953|
|Mr. Douglas Liu||VP of Fin.||N/A||N/A||1964|
|Dr. Stuart E. Katz M.D.||VP of Operations||N/A||N/A||N/A|
Medifocus Inc., a medical technology company, develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate in Canada and the United States. The company owns technology platforms, including Endo-thermotherapy platform, a catheter-based focused heat technology platform that utilizes natural body openings to deliver microwave thermotherapy to the diseased sites; and Adaptive Phased Array (APA) Microwave Focusing platform, which directs focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. It also offers Prolieve Thermodilatation system, a medical device based on endo-thermotherapy for the treatment of benign prostatic hyperplasia. In addition, the company is developing APA 1000, a minimally invasive breast cancer treatment system, which is in pivotal Phase-III clinical trials. The company has a license agreement with Duke University for the development of heat-activated and tumor-targeted immunotherapy and gene therapy technology for the treatment of cancers and other diseases. Medifocus Inc. has a patent license agreement with Duke University for the development of heat-activated and tumor-targeted immunotherapy and gene therapy for the treatment of cancers and other diseases. The company is based in Toronto, Canada.
Medifocus Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.